Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,430.00GBp
20 Apr 2018
Change (% chg)

22.60 (+1.61%)
Prev Close
1,407.40
Open
1,419.00
Day's High
1,435.00
Day's Low
1,414.20
Volume
8,747,041
Avg. Vol
9,834,911
52-wk High
1,724.50
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £75,181.28
Shares Outstanding(Mil.): 4,918.63
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 38.75 30.95 32.74
EPS (TTM): 0.39 -- --
ROI: 7.58 14.84 14.38
ROE: 278.84 16.34 16.07

P&G's vitamin boost could signal more to come

LONDON/CHICAGO Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products.

20 Apr 2018

UPDATE 1-P&G's vitamin boost could signal more to come

* Health and wellness seen as attractive to younger consumers

20 Apr 2018

P&G to buy German Merck's consumer health unit for $4.2 billion

Procter & Gamble Co (P&G) has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets. | Video

20 Apr 2018

P&G to buy German Merck's consumer health unit for $4.2 billion

Procter & Gamble Co (P&G) has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.

20 Apr 2018

UPDATE 3-P&G to buy German Merck's consumer health unit for $4.2 bln

* Merck to update earnings guidance at Q1 results (Adds Breakingviews link)

20 Apr 2018

UPDATE 3-P&G to buy German Merck's consumer health unit for $4.2 bln

* Merck to update earnings guidance at Q1 results (Adds background on industry, M&A, implications for P&G business)

19 Apr 2018

Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

LONDON Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.

19 Apr 2018

Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

LONDON, April 18 Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.

19 Apr 2018

GSK flags pharma M&A ambitions by poaching Roche deal-maker

LONDON GlaxoSmithKline signaled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products.

18 Apr 2018

UPDATE 1-GSK flags pharma M&A ambitions by poaching Roche deal-maker

* GSK looks to boost drug pipeline with deal-making (Adds context on GSK drug pipeline, more details on Sin)

18 Apr 2018

Earnings vs. Estimates